Shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) have received a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among […]
Zacks Investment Research upgraded shares of Arbutus Biopharma (NASDAQ:ABUS – Get Rating) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $2.75 price objective on the biopharmaceutical company’s stock. According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, […]
Equities analysts forecast that Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) will post ($0.13) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Arbutus Biopharma’s earnings, with estimates ranging from ($0.18) to ($0.08). Arbutus Biopharma posted earnings of ($0.21) per share during the same quarter […]
Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) has received an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that […]
Shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages […]